Patient adherence and preference considerations in managing cardiovascular risk: Focus on single pill and amlodipine/atorvastatin fixed combination

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 61-66

  Aslam, Farhan ^a   Haque, Attiya ^a   Lee, Veronica ^a   Foody, JoAnne ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adherence; Amlodipine atorvastatin; Cardiovascular disease; Drug combination; Poly pharmacy

Indexed keywords

EID: 75749096893     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S4201     Document Type: Review

References (53)

1. American Heart Association. Heart Disease and Stroke Statistics: 2004 Update. Dallas, Tex: American Heart Association; 2003.
2. Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004;10:926-932.
3. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertension. 2000;13:3S-10S.
4. Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/ atorvastatin single-pilltherapy. Int J Clin Pract. 2005;59(7):839-846.
5. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation. 2007;115:2761-2788.
6. Jackson R, Lawes CMM, Bennertt DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascularrisk. Lancet. 2005;365:434-441.
7. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591-603.
8. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Guidelines for the management of arterial hypertension. Eur Heart J. 2007;28:1462-1536.
9. Kostis BK. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther. 2007;21:297-309.
10. Battleman DS, Peterson ED. Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing data from the National Health and Nutrition Examination Survey [abstract]. J Manag Care Pharm. 2004;10(2):186.
11. Heart Protection Study Collaborative Group. MRC/BHF health protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
12. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.
13. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9 Suppl:2-6.
14. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(15):E1-E6.
15. Bosworth HB, Dudley T, Olsen MK, et al. Racial differences in blood pressure control: potential explanatory factors. Am J Med. 2006;119(70): e9-e15.
16. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
17. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;47:1039-1048.
18. Wang PJ, Bohn RL, Knight E, et al. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med. 2002;17(7):504-511.
19. Schwartz JS, Mclaughlin T, Griffis D, et al. Adherence to chronic therapy among patients treated for hypertension, dyslipidemia or both [abstract]. J Am Coll Cardiol. 2003;41 suppl A:526A.
20. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
21. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Where do things stand on the eve of implementing the new Medicare Part D benefit? Data Watch. 2005;DOI 10.1377/hlthaff.W5.152.W5-152-W5-166.
22. Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11:306-312.
23. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC7 Report. JAMA. 2003;289:2560-2572.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (Adult treatment panel III) final report. Circulation. 2002;106:3143-3421.
25. Pettitt D, Karter AJ, Peng TY, et al. The impact of concurrent dyslipidemia and diabetes on hypertension management and goal attainment. Poster presented at: Annual meeting of the Society of General Internal Medicine; April 30-May 3, 2003, Vancouver, Canada.
26. Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27 suppl:S1-S24.
27. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
28. Simons LA, Levis G, Simons J, et al. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996; 164:208-211.
29. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10:697-704.
30. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32: 214-226.
31. Kogut SJ, Andrade SE, Willey C, et al. Non-adherence as a predictor of anti-diabetic drug therapy intensification. Pharmacoepidemiol Drug Saf. 2004;13:591-598.
32. Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardio vascular event: a retrospective cohort study. Can J Cardiol. 2005;21:485-488.
33. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
34. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006;151:185-191.
35. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
36. McKeage KM, Siddiqui AA. Amlodipine/atorvastatin fixed-dose combination. a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am J Cardiovasc Drugs. 2008;8(1):51-67.
37. Kass RS, Arena JP, DiManno D. Block of heart calcium channels by amlodipine: influence of drug charge on blocking activity. J Cardiovasc Pharmacol. 1988;12 suppl 7:S45-49.
38. Lipitor (atorvastatin calcium) Tablets. US Prescribing Information. New York, NY: Pfizer Inc; 2004.
39. Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol. 2003;92:670-676.
40. Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin Pharmacother. 2004;5(2):459-468.
41. Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(6):489-501.
42. Leibovitz E, Beniashvili M, Zimlichman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens. 2003;16(9 Pt 1):715-718.
43. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol. 2006;62:817-822.
44. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs. 2001; 61(12):1835-1881.
45. Murdoch D, Heel RC. Amlodipine: a review of its pharmacological and pharmacookinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1991;41(3):478-505.
46. Pfizer Labs. Caduet (amlodipine besylate/atorvastatin calcium) tablets: description [online]. Available from URL: http://www.caduet.com.
47. Blank R, LaSalle J, Reeves R, et al. Single pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodpine/atorvastatin Gemini Study). J Clin Hypertens. 2005;7(5):264-273.
48. Hobbs FD, Gensini G, Mancini GB, et al. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/ atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol. 2006;110:242-250.
49. Feldman R. Multiple risk intervention with a single-pill combination (amlodipine/atorvastatin) helps patients to attain recommended target levels for blood pressure and lipids (The JEWEL Program) [abstract no. P-129B]. J Clin Hypertens. 2006;8(6):457.
50. Preston RA, Harvey P, Herfert O, et al. A randomized, placebocontrolled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of co-administered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: The Respond trial. J Clin Pharmacol. 2007;47:1555-1569.
51. Tse HF, Ro YM, Howes L, et al. Multiple-risk intervention with single-pill amlodipine/atorvastatin therapy helps patients with diverse ethnicity attain recommended therapeutic goals for blood pressure and lipids (the GEMINI-AALA study) [abstract no. PO3-79]. J Hypertens. 2006;24 Suppl 6:329.
52. Flack JM, Victor R, Watson K, et al. Amlodipine/atorvastatin single pill improves goal attainment in the treatment of hypertension and dyslipidemia in African Americans: the CAPABLE trial [abstract]. J Clin Hypertens. 2006;8(6):456.
53. Patel BV, Leslie RS, Foody JM, et al. Adherence with single pill amlodipine/atorvastatin vs a two pill regimen. Vasc Health Risk Manag. 2008;4(3):673-681.